Lumen Bioscience co-founders Jim Roberts (left) and Brian Finrow

Lu­men lands an­oth­er DoD con­tract to treat Covid-re­lat­ed GI is­sues

The team at Lu­men Bio­science be­lieves that it can help pa­tients, in­clud­ing those in­fect­ed with Covid-19, through its plant-based drug LMN-301. Wednes­day, it an­nounced that the US Army is a be­liev­er too, hand­ing the com­pa­ny de­vel­op­ment fund­ing for its mon­o­clon­al an­ti­body cock­tail.

This deal builds on a pre­vi­ous grant from the US Army that helped fund pre­clin­i­cal de­vel­op­ment of the can­di­date to treat and pre­vent the gas­troin­testi­nal symp­toms of Covid-19, which of­ten takes a back seat to the con­cerns sur­round­ing res­pi­ra­to­ry is­sues. A study out of Wuhan found that GI symp­toms were found in 85% of se­vere­ly ill Covid-19 pa­tients, and 79% in sta­ble pa­tients.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA